A consortium of more than 75 research groups has received new funding to accelerate the development of new and innovative medicines combatting cancer. The Unit for the Discovery of Medicines at the Univ of Montreal (UDM2) is establishing a commercialization unit to move innovative discoveries along the drug discovery chain more quickly and effectively by linking its discovery portfolio and technological platforms to new partners that include innovative pharmaceutical companies.